| Isoprostane generation and function GL Milne, H Yin, KD Hardy, SS Davies, LJ Roberts Chemical reviews 111 (10), 5973-5996, 2011 | 355 | 2011 |
| Cytochromes P450 1A2 and 3A4 catalyze the metabolic activation of sunitinib GM Amaya, R Durandis, DS Bourgeois, JA Perkins, AA Abouda, KJ Wines, ... Chemical research in toxicology 31 (7), 570-584, 2018 | 72 | 2018 |
| Providing a new aniline bioisostere through the photochemical production of 1-aminonorbornanes D Staveness, TM Sodano, K Li, EA Burnham, KD Jackson, ... Chem 5 (1), 215-226, 2019 | 67 | 2019 |
| Cytochrome P450–catalyzed metabolism of cannabidiol to the active metabolite 7-hydroxy-cannabidiol JL Beers, D Fu, KD Jackson Drug Metabolism and Disposition 49 (10), 882-891, 2021 | 53 | 2021 |
| Role of cytochrome P450 enzymes in the metabolic activation of tyrosine kinase inhibitors KD Jackson, R Durandis, MJ Vergne International Journal of Molecular Sciences 19 (8), 2367, 2018 | 43 | 2018 |
| Cytochrome P450 3A4 and CYP3A5-catalyzed bioactivation of lapatinib JK Towles, RN Clark, MD Wahlin, V Uttamsingh, AE Rettie, KD Jackson Drug Metabolism and Disposition 44 (10), 1584-1597, 2016 | 43 | 2016 |
| Nonenzymatic free radical-catalyzed generation of 15-deoxy-Δ12, 14-prostaglandin J2-like compounds (deoxy-J2-isoprostanes) in vivo 1 KD Hardy, BE Cox, GL Milne, H Yin, IILJ Roberts Journal of lipid research 52 (1), 113-124, 2011 | 36 | 2011 |
| Interindividual variation in CYP3A activity influences lapatinib bioactivation JE Bissada, V Truong, AA Abouda, KJ Wines, RD Crouch, KD Jackson Drug Metabolism and Disposition 47 (11), 1257-1269, 2019 | 21 | 2019 |
| Vascular impact of cancer therapies: the case of BTK (Bruton tyrosine kinase) inhibitors MR Fleming, L Xiao, KD Jackson, JA Beckman, A Barac, JJ Moslehi Circulation research 128 (12), 1973-1987, 2021 | 16 | 2021 |
| HU-331 and oxidized cannabidiol act as inhibitors of human topoisomerase IIα and β JT Wilson, CA Fief, KD Jackson, SL Mercer, JE Deweese Chemical Research in Toxicology 31 (2), 137-144, 2018 | 16 | 2018 |
| Novel approaches to characterize individual drug metabolism and advance precision medicine KD Jackson, B Achour, J Lee, RM Geffert, JL Beers, BD Latham Drug metabolism and disposition 51 (10), 1238-1253, 2023 | 12 | 2023 |
| Detoxication versus bioactivation pathways of lapatinib in vitro: UGT1A1 catalyzes the hepatic glucuronidation of debenzylated lapatinib DT Nardone-White, JE Bissada, AA Abouda, KD Jackson Drug Metabolism and Disposition 49 (3), 233-244, 2021 | 11 | 2021 |
| Interindividual variability in cytochrome P450 3A and 1A activity influences sunitinib metabolism and bioactivation EA Burnham, AA Abouda, JE Bissada, DT Nardone-White, JL Beers, ... Chemical research in toxicology 35 (5), 792-806, 2022 | 10 | 2022 |
| Cytosolic enzymes generate cannabinoid metabolites 7-carboxycannabidiol and 11-nor-9-carboxytetrahydrocannabinol JL Beers, AK Authement, N Isoherranen, KD Jackson ACS Medicinal Chemistry Letters 14 (5), 614-620, 2023 | 8 | 2023 |
| Verifying in vitro‐determined enzyme contributions to cannabidiol clearance for exposure predictions in human through physiologically‐based pharmacokinetic modeling CHT Yeung, JL Beers, KD Jackson, AN Edginton CPT: Pharmacometrics & Systems Pharmacology 12 (3), 320-332, 2023 | 8 | 2023 |
| Association of lipid profile biomarkers with breast cancer by molecular subtype: analysis of the MEND study A Gupta, V Saraiya, A Deveaux, T Oyekunle, KD Jackson, O Salako, ... Scientific Reports 12 (1), 10631, 2022 | 8 | 2022 |
| Impact of cytochrome P450 variation on meperidine N-demethylation to the neurotoxic metabolite normeperidine JL Murray, SL Mercer, KD Jackson Xenobiotica, 2020 | 7 | 2020 |
| Kinase Inhibitors FDA Approved 2018–2023: Drug Targets, Metabolic Pathways, and Drug-Induced Toxicities BD Latham, RM Geffert, KD Jackson Drug Metabolism and Disposition 52 (6), 479-492, 2024 | 5 | 2024 |
| A Review of CYP-Mediated Drug Interactions: Mechanisms and In Vitro Drug-Drug Interaction Assessment J Lee, JL Beers, RM Geffert, KD Jackson Biomolecules 14 (1), 99, 2024 | 5 | 2024 |
| Cytochromes P450 2C8 and 3A catalyze the metabolic activation of the tyrosine kinase inhibitor masitinib BD Latham, DS Oskin, RD Crouch, MJ Vergne, KD Jackson Chemical research in toxicology 35 (9), 1467-1481, 2022 | 5 | 2022 |
